These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

935 related articles for article (PubMed ID: 25666752)

  • 21. Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis.
    Farhan MA; Carmine-Simmen K; Lewis JD; Moore RB; Murray AG
    PLoS One; 2015; 10(8):e0135245. PubMed ID: 26295809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer.
    Wazir U; Newbold RF; Jiang WG; Sharma AK; Mokbel K
    Oncol Rep; 2013 May; 29(5):1969-74. PubMed ID: 23503572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivo.
    Dormond O; Contreras AG; Meijer E; Datta D; Flynn E; Pal S; Briscoe DM
    J Immunol; 2008 Dec; 181(11):8088-95. PubMed ID: 19018001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ATP-site binding inhibitor effectively targets mTORC1 and mTORC2 complexes in glioblastoma.
    Neil J; Shannon C; Mohan A; Laurent D; Murali R; Jhanwar-Uniyal M
    Int J Oncol; 2016 Mar; 48(3):1045-52. PubMed ID: 26719046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.
    Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K
    Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predominance of mTORC1 over mTORC2 in the regulation of proliferation of ovarian cancer cells: therapeutic implications.
    Montero JC; Chen X; Ocaña A; Pandiella A
    Mol Cancer Ther; 2012 Jun; 11(6):1342-52. PubMed ID: 22496482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).
    García-Martínez JM; Alessi DR
    Biochem J; 2008 Dec; 416(3):375-85. PubMed ID: 18925875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapamycin-Resistant mTOR Activity Is Required for Sensory Axon Regeneration Induced by a Conditioning Lesion.
    Chen W; Lu N; Ding Y; Wang Y; Chan LT; Wang X; Gao X; Jiang S; Liu K
    eNeuro; 2016; 3(6):. PubMed ID: 28101526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer.
    Gulhati P; Cai Q; Li J; Liu J; Rychahou PG; Qiu S; Lee EY; Silva SR; Bowen KA; Gao T; Evers BM
    Clin Cancer Res; 2009 Dec; 15(23):7207-16. PubMed ID: 19934294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells.
    Hoshii T; Kasada A; Hatakeyama T; Ohtani M; Tadokoro Y; Naka K; Ikenoue T; Ikawa T; Kawamoto H; Fehling HJ; Araki K; Yamamura K; Matsuda S; Hirao A
    Proc Natl Acad Sci U S A; 2014 Mar; 111(10):3805-10. PubMed ID: 24567410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combinatorial Inhibition of mTORC2 and Hsp90 Leads to a Distinctly Effective Therapeutic Strategy in Malignant Pheochromocytoma.
    Zhang X; Gao F; Zhong S
    Curr Cancer Drug Targets; 2019; 19(9):698-706. PubMed ID: 30727894
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
    Fan QW; Weiss WA
    Methods Mol Biol; 2012; 821():349-59. PubMed ID: 22125077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells.
    Smrz D; Kim MS; Zhang S; Mock BA; Smrzová S; DuBois W; Simakova O; Maric I; Wilson TM; Metcalfe DD; Gilfillan AM
    Blood; 2011 Dec; 118(26):6803-13. PubMed ID: 22053105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin.
    Toschi A; Lee E; Xu L; Garcia A; Gadir N; Foster DA
    Mol Cell Biol; 2009 Mar; 29(6):1411-20. PubMed ID: 19114562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the in vivo safety profiles of Rictor inhibition using a zebrafish model.
    Cao Y; Jiang L; Zhao L; Zhou X; Wang N; Zhang P; Tang Y; Zhou J
    Curr Pharm Des; 2015; 21(12):1645-53. PubMed ID: 25557637
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
    Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
    Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.
    Goncharov DA; Kudryashova TV; Ziai H; Ihida-Stansbury K; DeLisser H; Krymskaya VP; Tuder RM; Kawut SM; Goncharova EA
    Circulation; 2014 Feb; 129(8):864-74. PubMed ID: 24270265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition.
    Breuleux M; Klopfenstein M; Stephan C; Doughty CA; Barys L; Maira SM; Kwiatkowski D; Lane HA
    Mol Cancer Ther; 2009 Apr; 8(4):742-53. PubMed ID: 19372546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.